During 1993 the indications for the use of angiotensin-converting enzyme (ACE) inhibitors
were expanded to include patients with left ventricular dysfunction and acute myocardial …

Angiotensin converting enzyme (ACE) inhibition and digoxin may be used in the
management of heart failure. Digoxin increases myocardial contractility in vitro, and has a …

Numerous clinical trials have highlighted the role of the renin‐angiotensin‐aldosterone
(RAA) system in the development and progression of heart failure. Over 30 randomized …

Objective.—This review of the pharmacologic treatment of heart failure due to left ventricular
systolic dysfunction summarizes the recommendations of the expert panel for the Agency for …

In recent years, there has been much attention devoted to the endocrine and neurohumoral
responses to myocardial failure, their participation in the pathophysiology of the disorder …

A number of important questions surrounding the treatment of systolic congestive heart
failure have been answered by randomised clinical trials completed within the past 2 years …

The angiotensin converting enzyme (ACE) inhibitors constitute a major breakthrough in the
medical management of congestive heart failure. The incidence of side effects with these …

The success of angiotensin-converting enzyme (ACE) inhibitors in reducing morbidity and
mortality in patients with heart failure has led to investigations of other inhibitors of the renin …

Activity of the renin-angiotensin-aldosterone system (RAAS) is increased in heart failure.
Agents which act on the RAAS can be expected to benefit these patients. Recent trials which …

Treatment of heart failure is aimed at controlling intravascular volume, improving the
contractile state of the myocardium when systolic function is impaired, and reducing …